Efficacy and Safety of Regorafenib in the Treatment of Bone Sarcomas
This study has been identified as potentially high impact.
OE's AI-driven High Impact metric estimates the influence a paper is likely to have by integrating signals from both the journal in which it is published and the scientific content of the article itself.
Developed using state-of-the-art natural language processing, the OE High Impact model more accurately predicts a study's future citation performance than journal impact factor alone.
This enables earlier recognition of clinically meaningful research and helps readers focus on articles most likely to shape future practice.
Efficacy and safety of regorafenib in the treatment of bone sarcomas: systematic review and meta-analysis.
BMC Cancer . 2025 Feb 19;25(1):302.Five randomized controlled trials including 179 patients with metastatic or recurrent bone sarcomas were included in this systematic review and meta-analysis comparing regorafenib monotherapy vs. placebo. Pooled outcomes of interest included 3- and 6-month progression-free survival (PFS), overall survival (OS) at multiple timepoints, and adverse events (AEs). Regorafenib significantly improved 3-month PFS and 6-month PFS with no improvement in OS. Adverse events were more frequent in the regorafenib group. The findings suggest regorafenib improves short-term disease control but not long-term survival, with a higher incidence of manageable side effects.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
